Aclerastide

Drug Profile

Aclerastide

Alternative Names: DSC-127; NorLeu3-A(1-7)

Latest Information Update: 23 Nov 2015

Price : $50

At a glance

  • Originator University of Southern California
  • Developer Derma Sciences; US Biotest Inc
  • Class Hexanoic acids; Peptides; Skin disorder therapies
  • Mechanism of Action Angiotensin receptor agonists; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Diabetic foot ulcer

Highest Development Phases

  • Suspended Radiation-induced skin damage; Scars
  • Discontinued Diabetic foot ulcer

Most Recent Events

  • 12 Nov 2015 Suspended - Preclinical for Scars in USA (Topical)
  • 12 Nov 2015 Suspended - Preclinical for Radiation-induced skin damage (Prevention) in USA (Topical)
  • 12 Nov 2015 Suspended - Preclinical for Radiation-induced skin damage in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top